ArticleAesthetic surgery journal. Open forum2025
"Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.
Article in Aesthetic surgery journal. Open forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of "Ozempic Face".Dermatology and therapy · 2026Article
- Psychosocial Outcomes and Aesthetic Expectations in Female Patients Undergoing Body Contouring After GLP-1-Induced Weight Loss: A Prospective Pilot Comparative Study with Post-Bariatric Patients.Aesthetic plastic surgery · 2026Article
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.Dermatology and therapy · 2026Review
- Topical Volumizing Cream Improves Facial Volume and Skin Health in Adults With Rapid Weight Loss From Pharmacologic (GLP-1/GIP Agonists), Surgical, or Behavioral Interventions.Journal of cosmetic dermatology · 2026Article
- Response by Sharp to ""Ozempic Face": Construct, Consequence, or Clinical Entity?" by Daneshgaran et al.Aesthetic surgery journal. Open forum · 2026Article
- Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review.Aesthetic surgery journal. Open forum · 2026Review
- Interest in Facial Volume Restorative Procedures With the Rise in "Ozempic Face": A Google Trends Analysis.Plastic and reconstructive surgery. Global open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists have gained popularity after clinical trials demonstrated their weight-loss potential. The term "Ozempic® face" has been coined to describe the exaggerated volume loss from semaglutide therapy, resulting in advanced facial aging. Objectives: The authors of this study aim to review plastic surgery publications discussing GLP-1 receptor agonists and characterize the public's perception of the effect of these medications on weight loss. Methods: A systematic review of the PubMed database was conducted to identify articles discussing GLP-1 receptor agonist use in plastic surgery. Articles in non-English languages or on nonhuman subjects were excluded. Bias assessment was completed using standardized checklists. Google Trends was used to track public interest in these medications and their effect on face and body morphology. Results: Twenty-three articles were identified, revealing that (1) several injectable drugs are available for weight loss, (2) GLP-1 receptor agonists cause morphological changes resembling advanced aging, (3) surgical and nonsurgical options exist to address these changes, (4) adverse effects of these medications help guide perioperative management, and (5) important contraindications exist to their use. Online searches for "Ozempic® face" were linked to rising searches for "face filler" and "plastic surgeons." Conclusions: As the unintended morphological changes of GLP-1 receptor agonists become increasingly reported, so does the public interest in seeking rejuvenation procedures. Although limited by study biases, this systematic review can help the plastic surgery community prepare for the rising needs of this patient population by understanding the risk and benefit profile of GLP-1 receptor agonists and developing clear clinical practice guidelines. Level of Evidence 4 Therapeutic:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.